Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine antimycobacterial drug pharmacokinetics (PK) and
pharmacodynamics (PD) in patients with cystic fibrosis (CF) to improve treatment of
nontuberculous mycobacterial (NTM) lung disease.
Phase:
N/A
Details
Lead Sponsor:
University of Colorado, Denver
Collaborators:
Colorado Clinical & Translational Sciences Institute Cystic Fibrosis Foundation Cystic Fibrosis Foundation Therapeutics